Dabigatran is the newest generation of oral anticoagulant drugs - direct thrombin inhibitors (DTIs), belonging to non-peptide thrombin inhibitors and instead specifically and selectively blocks the thrombin activity (free or bound) to prevent coagulation. Dabigatran targets the preventative and clinical treatment needs of acute and chronic thromboembolic disease.

CAS NO:211915-06-9

EC NO:

Molecular Formula:C₃₄H₄₁N₇O₅

Molecular Weight:627.7332

Synonyms:;Pradaxa;Dabigatran etexilate;BIBR-1048MS;BIBR-1048;ethyl N-[(2-{[(4-{[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-pyridin-2-yl-beta-alaninate;Alanine,N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-,ethyl ester;β-Alanine,N-[[2-[[[4-[[[(hexyloxy)carbonyl] amino]iminomethyl] phenyl]amino] methyl]-1-methyl-1H-bezimidazol-5-yl]carbonyl]-N-2-pridinyl-ethyl ester;Dabigatran free base;Dabigatran etexilate mesylate base;N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-β-Alanine, ethyl ester;

Molecular Structure: